Sarepta Therapeutics (SRPT) Posts Slightly Smaller Q1 Loss
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.13 better than the analyst estimate of ($1.28).
The Company had $140.6 million in cash, cash equivalents, short-term investments and restricted cash as of March 31, 2016 compared to $204.0 million as of December 31, 2015, a decrease of $63.4 million. The decrease was due to the use of cash to fund the Company’s ongoing operations, commercial launch activities and related inventory build.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan is worried about further S&P 500 sell-off potential
- PepsiCo (PEP) tops earnings, revenue expectations in Q1
- Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!